📊 ALUR Key Takeaways
Is Allurion Technologies, Inc.. (ALUR) a Good Investment?
Allurion Technologies exhibits severe financial distress with negative stockholders' equity of -$82.9M, indicating the company is technically insolvent. The company is burning cash at an unsustainable rate (-$24.2M free cash flow) while generating only $11.6M in revenue, demonstrating a fundamental mismatch between operations and business model viability. Without immediate operational profitability or significant capital injection, the company faces existential liquidity challenges.
Allurion’s fundamentals are severely impaired: despite a solid 68.5% gross margin, the company is generating extreme operating and net losses relative to its revenue base, with operating margin of -205.4% and free cash flow margin of -208.6%. Financial health is highly stressed by negative stockholders’ equity, heavy leverage, weak interest coverage, and limited cash relative to ongoing burn, which makes the current growth profile low quality until losses and cash outflows materially improve.
Why Buy Allurion Technologies, Inc.. Stock? ALUR Key Strengths
- Strong gross margin of 68.5% indicates the core product has inherent profitability potential
- Adequate current ratio of 1.26x provides near-term liquidity buffer
- Operating in specialized medical device sector with addressable market opportunity
- Gross margin of 68.5% indicates the core product economics can support attractive unit-level profitability
- Current ratio of 1.26x suggests near-term obligations are not yet in immediate default territory
- Revenue base of $11.62M shows the business has commercial activity rather than being purely pre-revenue
ALUR Stock Risks: Allurion Technologies, Inc.. Investment Risks
- Negative stockholders' equity of -$82.9M represents technical insolvency and equity wipeout risk
- Operating cash burn of -$23.6M annually with only $6.1M cash on hand creates acute solvency risk
- Operating margin of -205.4% and net margin of -195.6% indicate business model cannot support current cost structure; revenue would need to triple just to approach breakeven
- Long-term debt of $47.2M against negative equity and negative cash flow creates refinancing risk
- No insider purchases in last 90 days despite distressed valuation suggests lack of management confidence
- Negative operating cash flow of $23.63M and free cash flow of $24.24M imply an unsustainable cash burn relative to only $6.14M of cash
- Negative stockholders’ equity of $82.93M signals a deeply weakened balance sheet and limits financial flexibility
- Long-term debt of $47.22M and interest coverage of -10.5x indicate material solvency and refinancing risk
Key Metrics to Watch
- Quarterly revenue growth rate and path to $50M+ annual revenue needed for viability
- Monthly cash burn rate and runway to profitability or capital raise deadline
- Gross margin sustainability and operating expense reduction progress toward 50%+ net margins
- Quarterly revenue growth versus operating expense growth
- Cash runway, operating cash burn, and any improvement in stockholders’ equity
Allurion Technologies, Inc.. (ALUR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Allurion Technologies, Inc.. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
ALUR Profit Margin, ROE & Profitability Analysis
ALUR vs Healthcare Sector: How Allurion Technologies, Inc.. Compares
How Allurion Technologies, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Allurion Technologies, Inc.. Stock Overvalued? ALUR Valuation Analysis 2026
Based on fundamental analysis, Allurion Technologies, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Allurion Technologies, Inc.. Balance Sheet: ALUR Debt, Cash & Liquidity
ALUR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Allurion Technologies, Inc..'s revenue has declined by 50% over the 5-year period, indicating business contraction. The most recent EPS of $-3.20 indicates the company is currently unprofitable.
ALUR Revenue Growth, EPS Growth & YoY Performance
ALUR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.7M | -$1.5M | $-1.53 |
| Q2 2025 | $3.4M | -$1.5M | $-1.28 |
| Q1 2025 | $5.6M | $5.6M | $0.20 |
| Q3 2024 | $5.4M | -$2.2M | $-0.10 |
| Q2 2024 | $11.8M | -$2.2M | $-0.05 |
| Q1 2024 | $9.4M | $5.6M | $0.11 |
| Q3 2023 | $16.1M | -$5.4M | $-0.53 |
| Q2 2023 | $13.0M | -$5.4M | $-0.82 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Allurion Technologies, Inc.. Dividends, Buybacks & Capital Allocation
ALUR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Allurion Technologies, Inc.. (CIK: 0001964979)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ALUR
What is the AI rating for ALUR?
Allurion Technologies, Inc.. (ALUR) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ALUR's key strengths?
Claude: Strong gross margin of 68.5% indicates the core product has inherent profitability potential. Adequate current ratio of 1.26x provides near-term liquidity buffer. ChatGPT: Gross margin of 68.5% indicates the core product economics can support attractive unit-level profitability. Current ratio of 1.26x suggests near-term obligations are not yet in immediate default territory.
What are the risks of investing in ALUR?
Claude: Negative stockholders' equity of -$82.9M represents technical insolvency and equity wipeout risk. Operating cash burn of -$23.6M annually with only $6.1M cash on hand creates acute solvency risk. ChatGPT: Negative operating cash flow of $23.63M and free cash flow of $24.24M imply an unsustainable cash burn relative to only $6.14M of cash. Negative stockholders’ equity of $82.93M signals a deeply weakened balance sheet and limits financial flexibility.
What is ALUR's revenue and growth?
Allurion Technologies, Inc.. reported revenue of $11.6M.
Does ALUR pay dividends?
Allurion Technologies, Inc.. does not currently pay dividends.
Where can I find ALUR SEC filings?
Official SEC filings for Allurion Technologies, Inc.. (CIK: 0001964979) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ALUR's EPS?
Allurion Technologies, Inc.. has a diluted EPS of $-3.43.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ALUR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Allurion Technologies, Inc.. has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ALUR stock overvalued or undervalued?
Valuation metrics for ALUR: ROE of N/A (sector avg: 15%), net margin of -195.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ALUR stock in 2026?
Our dual AI analysis gives Allurion Technologies, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ALUR's free cash flow?
Allurion Technologies, Inc..'s operating cash flow is $-23.6M, with capital expenditures of $611.0K. FCF margin is -208.6%.
How does ALUR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -195.6% (avg: 12%), ROE N/A (avg: 15%), current ratio 1.26 (avg: 2).